June, 2017:

• Inhibiting CFH May Improve Responses to Rituximab in CLL
• Savolitinib Shows Promise for MET-driven Papillary Renal Cell Carcinoma
• Dermatomyositis and Cancer Risk
• Tamoxifen- and Placebo-induced Symptoms Yield Similar Adherence Rates to Breast Cancer Prophylactics
• Adjuvant Anthracycline Does Not Improve DFS in TOP2A-normal Breast Cancer
• Ginger Does Not Improve Chemotherapy-associated Nausea
• Q&A With Dr Shaw: ALK/ROS1 Inhibition in Patients With Non-small Cell Lung Cancer
• Restoring ASPP1 May Improve Outcomes in Clear Cell RCC
• Tamoxifen or Exemestane With Ovarian Function Suppression Prolongs Breast Cancer-free Interval
• Immunotherapy of Advanced Colorectal Cancer By Enlisting Bystander T Cells
• TPX-0005 Granted Orphan Drug Designation for Non-small Cell Lung Cancer
• Palbociclib Plus Fulvestrant Improves PFS Among Premenopausal Patients With Breast Cancer
• Absolute Lymphocyte Counts Predictive of Survival With CLL Post-FCR
• In Focus: Blinatumomab for Non-Hodgkin Lymphoma
• Evofosfamide Not Recommended in First-line Sarcoma Treatment
• Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib
• Favorable 4-year Outcomes for Patients With Myeloma Treated With Elotuzumab
• TKI Discontinuation for Patients With CML Could Save Billions
• Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation
• FDA Approves Subcutaneous Rituximab and Hyaluronidase Human for Blood Cancers
• MRI Imaging in Adjunct With Mammograms Improves Secondary Breast Cancer Detection
• FDA Approves Dabrafenib and Trametinib for BRAF^V600E-mutant NSCLC
• First-line Nivolumab Fails To Prolong Survival in Stage IV NSCLC
• Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma
• Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma
• Supreme Court Ruling Should Hasten Arrival of Biosimilars, But Uncertainties Remain
• Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine
• Early Taxane Switching May Improve PSA Response Rates in Prostate Cancer
• Once-daily Radiotherapy Not Superior to Twice-daily in SCLC
• Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach
• Phase 3 Vadastuximab Talirine Trials Halted Due to Deaths
• Potential Drug- and Herb-Drug Interactions Among Patients With Cancer
• Intervention-guided Program Improves Weight Loss Among African American Breast Cancer Survivors
• Dietary Nutrients and Oncogenic HPV Infections
• Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma
• FDA Expands Daratumumab Approval for Multiple Myeloma
• In Focus: Abemaciclib for Advanced Breast Cancer
• PD-L2 Expression May Be Associated With Response to Pembrolizumab in HNSCC
• Phase 2 Trial of Poly-ICLC Vaccination for Solid Tumors
• Phase 2 Trial of GL-0817 With Cyclophosphamide for Squamous Cell Carcinoma of the Oral Cavity
• Future Treatment Modalities in Sarcoma: Insights From ASCO 2017
• OS Milestone Rate May Be Useful Secondary Endpoint in NSCLC Trials
• Phase 2 Trial of SBRT for Patients With Inoperable Head and Neck Cancer
• Study of Shoulder Disability Among Patients With Head and Neck Cancer Post-surgery
• Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer
• HBV Vaccine Can Prevent Non-Hodgkin Lymphoma in Adolescents
• Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer
• Momelotinib vs Ruxolitinib for Patients With Myelofibrosis
• Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck
• Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?
• Palifosfamide With Platinum Doublet Fails To Prolong Survival in SCLC
• Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer
• Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer
• Engagement Is Survival: My Take on ASCO 2017
• Mitigation of Anticancer Drug Wastage Could Save 17% of Costs
• Response-based Therapy Intensification Improves Survival in Adult ALL
• aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer
• Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy
• Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials
• Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN
• Cryosurgery: The Future of Breast Cancer Treatment?
• Burtomab Granted Breakthrough Therapy Designation for Metastatic Neuroblastoma
• FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer
• Prolonged PFS With Brentuximab Vedotin in Cutaneous T Cell Lymphoma
• Intermittent Letrozole May Benefit Some Patients With Breast Cancer
• Pembrolizumab Active in Advanced Gastric Cancer
• Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD
• Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment
• High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer
• Momelotinib for Previously Treated Patients With Myelofibrosis
• Gastric Linitis Plastica Diagnosis Uses Endoscopic and Radiologic Studies Approach
• Dabrafenib Plus Trametinib Promising in Melanoma
• Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer
• Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer
• Immunotherapy Shows Promise in Patients With Melanoma Brain Metastases
• Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases
• Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer
• Poorer DLBCL Survival Outcomes Linked to Dual Expression of MYC, BCL2
• TREnd: Adding Palbociclib to Endocrine Therapy Provides Clinical Benefits in Breast Cancer
• MARIANNE Update: T-DM1 Does Not Significantly Improve Survival in HER2+ Breast Cancer
• Dual HER2 Blockade Superior in HER2+ HR+ Breast Cancer
• Establishing a Short-term Response Endpoint for mCRPC Trials
• Electronic Patient-reported Outcome System Improves Survival Among Patients With Cancer
• Vemurafenib Active in BRAF^V600-mutant NSCLC
• Abemaciclib Plus Fulvestrant Is Effective Therapy in Endocrine-resistant Breast Cancer
• PALOMA-1 Update: Survival With Palbociclib Not Significantly Improved in ER+/HER2- Breast Cancer
• Aldoxorubicin Improves Outcomes in Relapsed/Refractory Sarcoma
• Korean Red Ginseng Improves Cancer-related Fatigue in Colorectal Cancer
• Personalizing Care for Patients With Sarcoma
• Sarcoma: Next-generation Sequencing Has Implications for Diagnosis and Treatment
• Promising Activity Reported for Nivolumab in Gynecologic Cancers
• Yoga Improves Sleep Disorders, Fatigue in Patients With Cancer
• Endometrial Cancer: Adjuvant Taxane Plus Platinum Agent Does Not Improve Outcomes
• Buparlisib Plus Fulvestrant Effective But Increases Toxicity in Breast Cancer
• Q&A With Michael A. Dyer, MD: Unraveling the Retinoblastoma Epigenome
• Cervical Cancer Progression More Likely With HIV Infection
• Midtreatment FDG-PET-Driven RT Escalation Promising in NSCLC
• Better Functional Outcomes With Stereotactic Conformal Radiotherapy for Brain Tumors
• CML: Patient Study Links Insurance Status at Diagnosis and Overall Survival